Home・Stock List・Glaukos Corp

Glaukos Corp

Closed

SectorHealthcare

171.07 2.74

Buy Sell

Overview

Share price change

24h

Current

Min

166.51

Max

173.49

Key metrics
By Trading Economics
Income	114M -20M
Sales	7.5M 151M
EPS	-0.18
Profit margin	-13.139
Employees	1,094
EBITDA	124M -5.3M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+11.51% upside

Dividends
By Acuity
Next Earnings	28 Oct 2026

Market Stats
By TradingEconomics
Market Cap	1.8B 8.9B
Previous open	168.33
Previous close	171.07

News Sentiment

By Acuity

50%

151 / 340 Healthcare

Glaukos Corp Chart

Past performance is not a reliable indicator of future results.

Related News

3 Aug 2026, 20:06 UTC

Glaukos Corp shares are higher amid positive market sentiment, with the S&P 500 and Nasdaq 100 also gaining. The stock remains above its 20-day moving average.

31 Jul 2026, 19:45 UTC

News

Glaukos shares are lower today despite H.C. Wainwright raising the price target to $195 from $168. Trading volume has been unusually high.

30 Jul 2026, 21:31 UTC

News

Glaukos Corp shares are lower in after-market trading, tracking declines in the Health Care Equipment sector. UBS raised its price target to $172.

29 Jul 2026, 21:22 UTC

Social Media

News

Glaukos Corp reported record net sales of $185.6 million in Q2 2026, raising its full-year revenue guidance to $680 million to $700 million. Shares are higher in after-market trading.

28 Jul 2026, 17:46 UTC

News

Glaukos Corp shares are lower after UBS initiated coverage with a Neutral rating, overshadowing Stifel's Buy rating and $175 price target.

27 Jul 2026, 19:16 UTC

Glaukos Corp shares are lower today, despite an initial gain. Broader market trends are affected by a significant drop in oil prices.

24 Jul 2026, 19:56 UTC

Glaukos Corp. shares are trading higher today, maintaining a cumulative gain since Thursday and remaining above their 20-day moving average.

21 Jul 2026, 17:41 UTC

Glaukos Corp shares are lower today amid a decline in the Health Care Equipment sub-sector, reversing the recent trend of higher daily closes.

Peer Comparison

Price change

Glaukos Corp Forecast

Price Target

By TipRanks

11.51% upside

12 Months Forecast

Average 185.91 USD 11.51%

High 215 USD

Low 153 USD

Based on 13 Wall Street analysts offering 12 month price targets forGlaukos Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Glaukos Corp - Dist in the past 3 months.

Sentiment

By Acuity

151 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.